Bicyclo[1.1.1]pentane as a Phenyl Isosteric Replacement

In medicinal chemistry, phenyl rings are often replaced with bioisosteres to optimize druglike properties. Bicyclo[1.1.1]pentane (BCP) is a widely used sp 3 -rich phenyl bioisostere offering improved metabolic stability and reduced lipophilicity. Herein, we report a retrospective analysis of BCP deployment in 24 internal drug discovery projects across target classes. Analysis of matched molecular pairs from the 7 structure-enabled projects with primary assay data revealed that 46% retained activity, 17% showed minimal loss (1- to 3-fold), 13% showed partial loss (3- to 10-fold), and 24% showed significant loss (>10-fold) relative to the phenyl analog with terminal BCP replacements outperforming scaffold replacements. BCP analogs showed improved lipophilic efficiency (mean ΔLipE = 0.88), particularly when the phenyl ring did not engage in π-mediated contacts. These findings demonstrate that successful bioisosteric replacement requires evaluating spatial accessibility and electrostatic character above and below the phenyl plane, structural role (terminal versus scaffold), and specific protein–ligand interactions, rather than geometric equivalence alone.